TY - JOUR AU - Tahir, Stephen K. AU - Smith, Morey L. AU - Hessler, Paul AU - Rapp, Lisa Roberts AU - Idler, Kenneth B. AU - Park, Chang H. AU - Leverson, Joel D. AU - Lam, Lloyd T. PY - 2017 DA - 2017/06/02 TI - Potential mechanisms of resistance to venetoclax and strategies to circumvent it JO - BMC Cancer SP - 399 VL - 17 IS - 1 AB - Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating patients with various hematologic malignancies. As with any targeted cancer therapy, it is critically important to identify potential mechanisms of resistance, both for patient stratification and developing strategies to overcome resistance, either before it develops or as it emerges. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-017-3383-5 DO - 10.1186/s12885-017-3383-5 ID - Tahir2017 ER -